Your browser doesn't support javascript.
loading
Development of a Nationally Representative Coordinated Registry Network for Prostate Ablation Technologies.
Golan, Ron; Bernstein, Adrien; Sedrakyan, Art; Daskivich, Timothy J; Du, Dongyi T; Ehdaie, Behfar; Fisher, Benjamin; Gorin, Michael A; Grunberger, Ivan; Hunt, Bradley; Jiang, Hongying H; Kim, Hyung L; Marinac-Dabic, Danica; Marks, Leonard S; McClure, Timothy D; Montgomery, Jeffrey S; Parekh, Dipen J; Punnen, Sanoj; Scionti, Stephen; Viviano, Charles J; Wei, John T; Wenske, Sven; Wysock, James S; Rewcastle, John; Carol, Mark; Oczachowski, Marc; Hu, Jim C.
Afiliação
  • Golan R; Department of Urology, New York Presbyterian-Weill Cornell Medical College, New York, New York.
  • Bernstein A; Department of Urology, New York Presbyterian-Weill Cornell Medical College, New York, New York.
  • Sedrakyan A; Department of Healthcare Policy and Research, Weill Cornell Medical College, New York, New York.
  • Daskivich TJ; Division of Urology, Cedars Sinai Medical Center, Los Angeles, California.
  • Du DT; Center for Devices and Radiological Health, United States Food and Drug Administration, Silver Spring, Maryland.
  • Ehdaie B; Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Fisher B; Center for Devices and Radiological Health, United States Food and Drug Administration, Silver Spring, Maryland.
  • Gorin MA; Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Grunberger I; Division of Urology, New York Presbyterian-Brooklyn Methodist Hospital, Brooklyn, New York.
  • Hunt B; Center for Devices and Radiological Health, United States Food and Drug Administration, Silver Spring, Maryland.
  • Jiang HH; Center for Devices and Radiological Health, United States Food and Drug Administration, Silver Spring, Maryland.
  • Kim HL; Division of Urology, Cedars Sinai Medical Center, Los Angeles, California.
  • Marinac-Dabic D; Center for Devices and Radiological Health, United States Food and Drug Administration, Silver Spring, Maryland.
  • Marks LS; Department of Urology, University of California-Los Angeles, Los Angeles, California.
  • McClure TD; Department of Urology, New York Presbyterian-Weill Cornell Medical College, New York, New York.
  • Montgomery JS; Department of Urology, University of Michigan, Ann Arbor, Michigan.
  • Parekh DJ; Department of Urology, University of Miami, Miami, Florida.
  • Punnen S; Department of Urology, University of Miami, Miami, Florida.
  • Scionti S; Vituro Health, Sarasota, Florida.
  • Viviano CJ; Center for Devices and Radiological Health, United States Food and Drug Administration, Silver Spring, Maryland.
  • Wei JT; Department of Urology, University of Michigan, Ann Arbor, Michigan.
  • Wenske S; Department of Urology, New York Presbyterian-Columbia University Medical Center, New York, New York.
  • Wysock JS; Department of Urology, New York University Langone Medical Center, New York, New York.
  • Rewcastle J; Department of Urology, University of Southern California, Los Angeles, California.
  • Carol M; SonaCare Medical, Charlotte, North Carolina.
  • Oczachowski M; EDAP-TMS, Vaulx-en-Velin, France.
  • Hu JC; Department of Urology, New York Presbyterian-Weill Cornell Medical College, New York, New York. Electronic address: JCH9011@med.cornell.edu.
J Urol ; 199(6): 1488-1493, 2018 06.
Article em En | MEDLINE | ID: mdl-29307684
PURPOSE: The accumulation of data through a prospective, multicenter coordinated registry network is a practical way to gather real world evidence on the performance of novel prostate ablation technologies. Urological oncologists, targeted biopsy experts, industry representatives and representatives of the FDA (Food and Drug Administration) convened to discuss the role, feasibility and important data elements of a coordinated registry network to assess new and existing prostate ablation technologies. MATERIALS AND METHODS: A multiround Delphi consensus approach was performed which included the opinion of 15 expert urologists, representatives of the FDA and leadership from high intensity focused ultrasound device manufacturers. Stakeholders provided input in 3 consecutive rounds with conference calls following each round to obtain consensus on remaining items. Participants agreed that these elements initially developed for high intensity focused ultrasound are compatible with other prostate ablation technologies. Coordinated registry network elements were reviewed and supplemented with data elements from the FDA common study metrics. RESULTS: The working group reached consensus on capturing specific patient demographics, treatment details, oncologic outcomes, functional outcomes and complications. Validated health related quality of life questionnaires were selected to capture patient reported outcomes, including the IIEF-5 (International Index of Erectile Function-5), the I-PSS (International Prostate Symptom Score), the EPIC-26 (Expanded Prostate Cancer Index Composite-26) and the MSHQ-EjD (Male Sexual Health Questionnaire for Ejaculatory Dysfunction). Group consensus was to obtain followup multiparametric magnetic resonance imaging and prostate biopsy approximately 12 months after ablation with additional imaging or biopsy performed as clinically indicated. CONCLUSIONS: A national prostate ablation coordinated registry network brings forth vital practice pattern and outcomes data for this emerging treatment paradigm in the United States. Our multiple stakeholder consensus identifies critical elements to evaluate new and existing energy modalities and devices.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Próstata / Neoplasias da Próstata / Sistema de Registros / Ressecção Transuretral da Próstata Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prognostic_studies Limite: Humans / Male País como assunto: America do norte Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Próstata / Neoplasias da Próstata / Sistema de Registros / Ressecção Transuretral da Próstata Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prognostic_studies Limite: Humans / Male País como assunto: America do norte Idioma: En Ano de publicação: 2018 Tipo de documento: Article